PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12636164-1	2003	PURPOSE: Aerosolized cyclosporine (aCsA) has proven to be an effective therapy for refractory acute and chronic rejection in lung transplant (LTx) patients.	Cyclosporine	21-33	acyl-CoA synthetase short chain family member 2	Homo sapiens	35-39	
19580368-2	2010	In our previously reported double-blinded, placebo-controlled trial comparing inhaled cyclosporine (ACsA) to aerosol placebo, the rate of bronchiolitis-free survival improved.	Cyclosporine	86-98	acyl-CoA synthetase short chain family member 2	Homo sapiens	100-104	
15065825-1	2004	Post-lung transplant use of aerosol cyclosporin (ACsA) is considered by examining the relationship between deposited aerosol dose and effect.	Cyclosporine	36-47	acyl-CoA synthetase short chain family member 2	Homo sapiens	49-53	
12636164-2	2003	The objective of this study is to evaluate the lung deposition and systemic absorption of aCsA after aerosolized cyclosporine administration in LTx patients in the immediate postoperative period.	Cyclosporine	113-125	acyl-CoA synthetase short chain family member 2	Homo sapiens	90-94